How should I manage a 76‑year‑old man with hypertension, hyperlipidemia, and diabetes whose hemoglobin fell from 10 g/dL to 9 g/dL while taking Xarelto (rivaroxaban) 20 mg twice daily and who reports no overt bleeding?

Management of Hemoglobin Drop in a 76-Year-Old on Rivaroxaban

You must immediately stop the rivaroxaban and investigate for occult bleeding, as this patient meets criteria for major bleeding based on the ≥2 g/dL hemoglobin drop, even without overt bleeding. 1

Immediate Assessment and Actions

Classify the Bleeding Severity

This patient has major bleeding by ACC definition because: 1

• Hemoglobin decreased ≥2 g/dL (from 10 to 9 g/dL)
• This threshold applies even without clinically overt bleeding or hemodynamic instability

Stop rivaroxaban immediately and do not restart until the bleeding source is identified and controlled. 1

Critical Dosing Error to Address

The prescribed dose of rivaroxaban 20 mg twice daily is incorrect and likely contributing to bleeding. 1, 2

• Standard rivaroxaban dosing for atrial fibrillation is 20 mg once daily (not twice daily) 1
• This patient is receiving double the approved dose, dramatically increasing bleeding risk
• At age 76 with baseline anemia (Hb 10), he was already at elevated bleeding risk before the dosing error 1

Investigate for Occult Bleeding

Even without reported overt bleeding, you must actively search for: 1, 3

Gastrointestinal sources (most common in elderly on anticoagulants):

• Perform fecal occult blood testing
• Ask specifically about black/tarry stools, maroon stools, or subtle changes in stool color 4
• Consider upper endoscopy and colonoscopy given age and anticoagulation 3

Genitourinary sources:

• Urinalysis for hematuria
• Assess for flank or suprapubic pain 3

Intracranial bleeding (critical given age):

• Assess for new headache, confusion, vision changes, weakness, or subtle cognitive changes
• Maintain low threshold for head CT in elderly patients on anticoagulants 3

Retroperitoneal bleeding:

• Examine for back, flank, or hip pain
• Consider CT abdomen/pelvis if unexplained hemoglobin drop persists 3

Assess Renal Function

Check creatinine clearance immediately using Cockcroft-Gault equation: 1

• Rivaroxaban is 33% renally excreted; renal impairment increases bleeding risk substantially 1, 5
• If CrCl 30-49 mL/min: standard dose should have been 15 mg once daily (not 20 mg twice daily) 1
• If CrCl 15-29 mL/min: rivaroxaban 15 mg once daily is recommended, though clinical trial data are limited 1
• If CrCl <15 mL/min: rivaroxaban is not recommended 1

Reversal Considerations

For this patient with major bleeding (≥2 g/dL Hb drop): 1

If bleeding is life-threatening or at a critical site:

• Administer andexanet alfa (specific reversal agent for rivaroxaban) 1, 2
• Alternative: 4-factor prothrombin complex concentrate if andexanet alfa unavailable 1

If bleeding is major but not immediately life-threatening:

• Supportive care with blood transfusion as needed
• Rivaroxaban half-life is 11-13 hours in elderly patients; drug effect will dissipate within 24-48 hours after discontinuation 5
• Consider activated charcoal if last dose was within 2-4 hours 2

Additional Risk Factors to Evaluate

Drug interactions that increase rivaroxaban levels and bleeding risk: 1

• Strong dual inhibitors of CYP3A4 and P-glycoprotein (ketoconazole, itraconazole, ritonavir, clarithromycin)
• Concomitant antiplatelet agents (aspirin, clopidogrel) dramatically increase bleeding risk 1, 3

Hepatic function:

• Check liver enzymes and coagulation studies
• Child-Pugh B or C cirrhosis is a contraindication to rivaroxaban 1

When to Restart Anticoagulation

Delay restarting if any of the following apply: 1

• Bleeding source not yet identified (current situation)
• Patient at high risk of rebleeding
• Surgical or invasive procedures planned

Consider restarting only when: 1

• Bleeding source identified and definitively treated
• Patient has high thromboembolic risk (assess CHA₂DS₂-VASc score)
• No ongoing bleeding risk

Use correct dosing when restarting: 1

• Base dose on renal function (CrCl)
• Standard atrial fibrillation dose: 20 mg once daily with evening meal (CrCl ≥50 mL/min)
• Reduced dose: 15 mg once daily (CrCl 30-49 mL/min or 15-29 mL/min)
• Consider 10 mg once daily for long-term therapy in elderly patients (≥76 years) with VTE to reduce bleeding risk 6

Critical Pitfalls to Avoid

• Never dismiss a ≥2 g/dL hemoglobin drop as "minor" – this is major bleeding by definition and carries increased mortality risk 1, 3
• Never continue anticoagulation at current dose when major bleeding criteria are met 1
• Never ignore the dosing error – twice-daily dosing of rivaroxaban for atrial fibrillation is incorrect and dangerous 1
• Never restart without identifying the bleeding source in elderly patients with renal impairment 1
• Never assume "no reported bleeding" means no bleeding – elderly patients may not recognize or report subtle bleeding 3, 4